Moneycontrol PRO
Upcoming Webinar:Watch Kushal Bhagi of Tortuga Wealth Managers decode how you can maximise your MF investments on Sept 21 @11am. Register Now

Buy Jubilant Pharmova; target of Rs 1000: ICICI Direct

ICICI Direct is bullish on Jubilant Pharmova recommended buy rating on the stock with a target price of Rs 1000 in its research report dated June 06, 2021.

June 08, 2021 / 06:35 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Jubilant Pharmova

Q4FY21 revenues were flat at Rs 1580 crore, up 0.7% YoY amid continued Covid-19 induced impact on radiopharma segment. Specialty pharma (which comprises Radiopharma) de-grew 23.5% YoY to Rs 602 crore. Generics remained flat at Rs 309 crore whereas CDMO segment grew 48% YoY to Rs 574 crore. Contract research & development grew 10% YoY to Rs 94 crore. EBITDA margins were down 419 bps YoY at 23.7% amid higher other expenditure. EBITDA de-grew 14.4% YoY to Rs 375 crore. Adjusted PAT degrew 13.7% to Rs 183 crore.


We maintain BUY rating on the stock with a TP of Rs 1000 (earlier Rs 850 pre-demerger) based on 12x on FY23E EPS of Rs 83.3.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Jun 8, 2021 07:29 am

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark